Effect of pioglitazone on serum high density lipoprotein [HDL] levels of type-2 diabetics

Objective: To study effect of Pioglitazone on serum high density lipoprotein levels in patients with type 2 diabetes mellitus

Study Design: Single blind randomized controlled trial

Place and Duration of Study: Department of medicine, Combined Military Hospital Multan from 1[st] Feb 2011 to 30[th] July 2012

Material and Methods: A total of 276 already diagnosed patients of diabetes mellitus type 2 between age of 30-80 years, presenting to the outpatient department of Combined Military Hospital Multan were selected. Type 2 diabetic patients were allocated group A or B using random allocation. Base line blood sugar fasting [BSF], glycosylated hemoglobin [HbAlc], high density lipoprotein [HDL] levels were taken. Group A was treated with Pioglitazone along with other hypoglycemic agents while group B was treated with only hypoglycemic agents and multivitamin tablets were added as placebo.After 12 weeks of treatment, serum HDL levels were measured to analyze effect of pioglitazone on serum HDL levels

Results: Pioglitazone group showed significant improvement in the serum HDL levels from baseline HDL 46.38 + 6.44mmol/L to 49.80+ 5.86 mmol/L after 12 weeks of therapy, [p = 0.001]

Conclusion: Pioglitazone when used in combination with other oral hypoglycemic agents has a beneficial effect on the serum HDL levels of the diabetics

Frequency of dyslipidemia in type-2 diabetes mellitus patients

To determine the frequency of dyslipdemias in patients of type -2 diabetes mellitus. Descriptive study. Combined Military Hospital Rawalpindi from January to July 2010. A total of 150 patients of DM fulfilling the required criteria were selected and subjected to fasting blood glucose, fasting lipid profile including total cholesterol, HDL- cholesterol, LDL- cholesterol and Triglyceride [TG] levels. The data obtained was analyzed using Statistical Package for Social Sciences [SPSS] version 10. Out of 150 patients 38% were female and 62% were male. The mean age of the patients was 57.63 years [SD +/- 8.09]. Minimum age was 36 years and maximum age was 77 years. Out of 150 patients dyslipidemia was present in 120[80%] patients. Hypertriglyceridemia was present in 120[80%] patients, raised LDL-cholesterol in 94 [62.7%] patients, decreased HDL-cholesterol in 88 [58.7%] patients, and raised levels of total cholesterol in 60 [40%] patients. Diabetic patients have a high frequency of dyslipidemias especially raised Triglycerides, therefore lipid profile is to be checked routinely and its management be given equal importance in addition to glycemic control